PBMs

Five things for pharma marketers to know: Thursday, August 17, 2017

Five things for pharma marketers to know: Thursday, August 17, 2017

By

Express Scripts to limit opioid coverage; Novo's diabetes drug lowers glucose levels in trial; startup aims to give doctors access to a patient's total costs

CVS relies on personalization in its ExtraCare loyalty program

CVS relies on personalization in its ExtraCare loyalty program

By

CVS has a pharmacy text program to remind patients to refill their prescriptions and alert them when their medications are ready.

Dr. Glen Stettin, Express Scripts

Dr. Glen Stettin, Express Scripts

Dr. Glen Stettin is the chief innovation officer of Express Scripts.

Five things for pharma marketers to know: Tuesday, March 14, 2017

Five things for pharma marketers to know: Tuesday, March 14, 2017

By

Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices

Five things for pharma marketers to know: Monday, March 6, 2017

Five things for pharma marketers to know: Monday, March 6, 2017

By

Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema

Five things for pharma marketers to know: Friday, February 24, 2017

Five things for pharma marketers to know: Friday, February 24, 2017

By

PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

By

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Five things for pharma marketers to know: Tuesday, November 8, 2016

Five things for pharma marketers to know: Tuesday, November 8, 2016

By

FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast

Power to the payers: PBMs leave behind a trail of tiers

Power to the payers: PBMs leave behind a trail of tiers

By

When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.

Five things for pharma marketers to know: Tuesday, August 30, 2016

Five things for pharma marketers to know: Tuesday, August 30, 2016

By

Walgreens Boots partners with PBM; Clinton proposes mental health plan; BI and Qualcomm to develop connected inhaler

PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

By

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.